Un­der fire, As­traZeneca hus­tles out a pri­ma­ry cut of the num­bers for its Covid-19 vac­cine sup­port­ing pos­i­tive ef­fi­ca­cy

Af­ter spend­ing the last 48 hours in a pres­sure cook­er of wide­spread crit­i­cism, As­traZeneca has up­dat­ed its da­ta on its con­tro­ver­sial Covid-19 vac­cine.

The phar­ma gi­ant an­nounced Wednes­day evening that their vac­cine was 76% ef­fec­tive in the pri­ma­ry analy­sis, a small slip on over­all ef­fi­ca­cy from its first cut of the da­ta. There was 100% ef­fi­ca­cy in pre­vent­ing se­vere dis­ease and hos­pi­tal­iza­tion. The slight re­vi­sion still bears up well in com­par­i­son with the 72% ef­fi­ca­cy rate cit­ed by J&J for its vac­cine, leav­ing As­traZeneca in a sol­id po­si­tion to win an emer­gency au­tho­riza­tion from the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER